Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.

EMBO molecular medicine·2026
Same author

Metabolic signatures in systemic autoimmune diseases: A state-of-the-art overview of systemic lupus erythematosus, primary Sjögren's syndrome, and systemic sclerosis.

Autoimmunity reviews·2026
Same author

Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.

Cell·2026
Same author

[Proposals from the French National Society of Internal Medicine on care pathways for patients with medical emergencies].

La Revue de medecine interne·2026
Same author

Cryopyrin-associated periodic syndrome: Understanding late diagnosis in adults from a French cohort.

Journal of the American Academy of Dermatology·2026
Same author

Mycoplasma pneumoniae pneumonia associated with severe neutropenia.

La Revue de medecine interne·2026

Related Experiment Videos

[Scleroderma renal crisis].

Luis Teixeira1, Amélie Servettaz, Marion Mehrenberger

  • 1Service de Médecine Interne, Hôpital Cochin, Centre de Référence pour les Vascularites Nécrosantes et la Sclérodermie Systémique, Assistance Publique-Hôpitaux de Paris (AP-HP) et Université Paris-Descartes, Paris.

Presse Medicale (Paris, France : 1983)
|December 13, 2006
PubMed
Summary

Scleroderma renal crisis (SRC), a severe complication of systemic sclerosis (SSc), necessitates prompt treatment with angiotensin-converting enzyme inhibitors (ACEI) to improve outcomes. Early intervention is key for managing this condition and its associated hypertension.

Related Experiment Videos

Area of Science:

  • Nephrology
  • Rheumatology
  • Internal Medicine

Background:

  • Scleroderma renal crisis (SRC) is a rare but severe complication of systemic sclerosis (SSc).
  • SRC typically manifests within the first four years of disease, predominantly in patients with diffuse SSc.
  • High-dose corticosteroid use is a recognized predictor of SRC development.

Purpose of the Study:

  • To summarize the definition, risk factors, and current management strategies for Scleroderma Renal Crisis (SRC).
  • To highlight the critical role of angiotensin-converting enzyme inhibitors (ACEI) in managing SRC.
  • To discuss the prognosis and potential need for renal replacement therapy in SRC patients.

Main Methods:

  • Literature review and synthesis of current clinical knowledge on SRC.
  • Analysis of factors predicting SRC development.
  • Evaluation of treatment outcomes with ACEI and other antihypertensive agents.

Main Results:

  • SRC is characterized by rapidly progressive renal insufficiency and/or severe hypertension in SSc patients.
  • Angiotensin-converting enzyme inhibitors (ACEI) have significantly improved SRC prognosis, though mortality remains a concern.
  • Effective blood pressure normalization is the primary treatment goal, often requiring ACEI and additional antihypertensives.

Conclusions:

  • Prompt diagnosis and management of SRC, particularly with ACEI, are crucial for improving patient outcomes.
  • While ACEI are central to treatment, other antihypertensives and potentially renal replacement therapy may be necessary.
  • Understanding SRC predictors like corticosteroid use aids in early identification and prevention.